Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299507
Status:
COMPLETED
Last Update Posted:
2012-11-28
First Post:
2006-03-03
Brief Title:
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration AMD
Sponsor:
Alcon Research
Organization:
Alcon Research
Study Overview
Official Title:
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate AA on visual acuity VA and lesion size when administered by posterior juxtascleral depot PJD every 3 months AA 15 mg or 6 months AA 15 mg AA 30 mg in patients with exudative age-related macular degeneration AMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None